Report on Stem Cell Policy and Funding under the Obama Administration

Report on Stem Cell Policy and Funding under the Obama Administration The document summarizes publicly known policy changes, funding increases, and a specific clinical trial issue. It contains no new allegations, financial flows, or misconduct involving high‑level officials, making it low‑value for investigative follow‑up. Key insights: Obama reversed Bush's limits on federal embryonic stem‑cell funding.; NIH stem‑cell funding increased; litigation (Sherley v. Sebelius) resolved in 2012.; FDA approved Geron's first hESC‑derived clinical trial in 2009, later placed on hold and withdrawn in 2010.